UNSPSC 51162208: Chlorpheniramine/methscopolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE105. This VA Drug Class (RE105) classifies this compound as belonging to the group BRONCHODILATORS, ANTICHOLINERGIC.

UNSPSC 51162208 Chlorpheniramine/methscopolamine is a Commodity code covering specific branded and generic pharmaceutical products — in this case, antihistamine and anticholinergic combination medications — that state and local government health systems, correctional facilities, and other public agencies procure through cooperative purchasing agreements and direct pharmaceutical supply contracts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in recent activity under this code, procuring generic multi-source pharmaceuticals and OTC products on behalf of participating state and local government facilities across multiple states including Oregon. Work solicited includes manufacturer pricing agreements and product supply arrangements requiring vendors to maintain relationships with authorized pharmaceutical wholesalers, comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and provide comprehensive product data including National Drug Codes, SKUs, and packaging configurations.

The geographic scope centers on MMCAP member states, with Minnesota and Oregon explicitly named as participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, seeking multiple contract awards for generic pharmaceuticals and OTC products with a response deadline of March 26, 2026. Evaluation criteria weighted price competitiveness at 75 percent, with administrative compliance, EDI capability, and fixed pricing each carrying smaller weights. Awarded vendors will have products available to authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) by May 15, 2026, with resulting contracts effective July 1, 2026 and running two years for new responders or through June 30, 2028 for incumbent amendments. The RFP does not disclose specific award values or budget ranges; vendors must pay a 3 percent administrative fee on all contract purchases and maintain commercial general liability insurance of $5,000,000 per occurrence.